Patients with cancer who received IV magnesium on the day of cisplatin administration had significant 27% lower odds of cisplatin-associated AKI compared with those who did not receive IV magnesium.

SAN FRANCISCO, CA—Srikanth Vallurupalli, MD, and colleagues from the University of Arkansas Medical Sciences, Little Rock, AR presented results at ACC.13, the American College of Cardiology’s 62 nd ...

Nearly 9 in 10 children given intravenous (IV) magnesium for refractory asthma ended up being admitted to the hospital, but new research suggests that may be partly due to a lack of clarity about the ...

The probability of spontaneous conversion to sinus rhythm (SVC) was increased with the intravenous administration of magnesium and potassium in patients with nonpermanent atrial fibrillation ...

Credit: Getty Images. Researchers investigated whether use of intravenous magnesium therapy for children with asthma was linked to subsequent hospitalization of these children. The administration of ...

Please provide your email address to receive an email when new articles are posted on . IV magnesium therapy administered after initial asthma treatment in the ED was associated with subsequent ...

Our study demonstrated that among patients with a baseline SMC of 1.4–1.8 mg/dL, the use of i.v. magnesium sulfate was associated with a greater increase in SMC than the use of oral magnesium oxide.

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women’s Hospital are the first and senior authors, respectively, of a paper published in ...

Please provide your email address to receive an email when new articles are posted on . IV magnesium for children with moderate-to-severe asthma exacerbations was associated with increased ...

A new research revealed how intravenous magnesium treatment given to stroke patients to protect the brain cells deprived of oxygen failed to improve stroke-related disability 3 months later.

Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of ...